Science
Mechanism of Action
Ethyl Caffeate exerts its biological effects by targeting key inflammatory pathways. It suppresses the activation of NF-κB, a central mediator of inflammation, which subsequently reduces the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2). Its inherent phenolic structure provides robust antioxidant capabilities, enabling it to scavenge free radicals and protect against oxidative damage, thereby supporting cellular integrity and delaying aging processes. Furthermore, it demonstrates a potential role in skin brightening through the inhibition of tyrosinase activity, which is crucial for melanin production.
Research
Clinical Evidence
Medium confidence0.5%
Key findings
- 01 Inhibited LPS-induced nitric oxide (NO) production with an IC50 of 5.5 μg ml−1 in RAW 264.7 macrophages (in vitro).
- 02 Significantly inhibited iNOS mRNA expression in LPS-treated macrophages by approximately 56% (in vitro).
- 03 Effectively inhibited LPS-mediated COX-2 protein expression by 45% in RAW 264.7 cells (in vitro).
- 04 Caused total inhibition of PGE2 production in LPS-stimulated RAW 264.7 cells (in vitro).
- 05 Topical application significantly abolished TPA-induced COX-2 expression in mouse skin (in vivo).
- 06 Topical application was more effective than 0.5% in inhibiting TPA-induced COX-2 expression in mouse skin (in vivo).
Transparency
Dusting Analysis
The provided research does not indicate that Ethyl Caffeate is commonly 'dusted' in cosmetic formulations. Its potential for irritation in concentrated forms suggests that proper formulation is crucial, rather than underdosing.
The Formula
Formulation
Stability
As a phenolic compound and ester, Ethyl Caffeate is sensitive to degradation by light, oxidation, and hydrolysis at extreme pH values. Optimal stability requires careful formulation, appropriate packaging (e.g., airtight, opaque containers), and refrigeration during storage.
Safety
Safety Profile
Comprehensive safety assessments by the Cosmetic Ingredient Review (CIR) or Scientific Committee on Consumer Safety (SCCS) are not available. GHS classifications for concentrated Ethyl Caffeate indicate potential hazards, specifically H315 ('Causes skin irritation') and H319 ('Causes serious eye irritation'), reported by 80% of notifications. There are no reported uses in the FDA's Voluntary Cosmetic Registration Program (VCRP), suggesting limited widespread use with reported safety data to the FDA.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Ethyl Caffeate demonstrates strong in vitro and some in vivo (mouse) anti-inflammatory, antioxidant, and potential skin brightening efficacy, but the lack of human clinical data and existing GHS warnings for irritation in concentrated forms necessitate further rigorous safety and efficacy testing before confident integration into precision skincare formulations.
Related
Similar Ingredients
Finding similar ingredients…